SCHEMBL17300221

SCHEMBL17300221

N#Cc1ccc(-c2ccc3c(c2)nc(-c2cccc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c2)c2c4ccccc4c4ccccc4c32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 7/20 0.43
▸ CYP3A4 P08684 6/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ LMNA P02545 4/20 0.43
▸ CYP2D6 P10635 4/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ CLK4 Q9HAZ1 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ TSHR P16473 3/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ ABCG2 Q9UNQ0 10/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ ADORA2A P29274 1/20 0.40
▸ ABCB1 P08183 5/20 0.40
▸ TP53 P04637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ USP2 O75604 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23861223 0.97 CYP1A2 (0.44) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL23861227 0.94 ABCG2 (0.44) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL17302716 0.93 ABCG2 (0.45) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL17300222 0.91 DHFR (0.41) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL23861216 0.90 ABCG2 (0.43) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL17302734 0.89 ABCG2 (0.46) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL17034939 0.87 CYP1A2 (0.42) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL20245170 0.85 CYP1A2 (0.47) CYP1A2CYP3A4MEN1ALDH1A1KMT2A
SCHEMBL17915195 0.84 MEN1 (0.47) CYP1A2MEN1ALDH1A1KMT2ALMNA
SCHEMBL17914804 0.84 MEN1 (0.47) CYP1A2CYP3A4MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10608189-B2 Condensed cyclic compounds and organic light-emitting devices including the same SAMSUNG DISPLAY CO., LTD. (KR) 2020-03-31 — — US disclosed
US-20150349275-A1 CONDENSED CYCLIC COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2015-12-03 — — US disclosed
US-20150349275-A1 CONDENSED CYCLIC COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2015-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10608189-B2 Condensed cyclic compounds and organic light-emitting devices including the same CRY1, CRY2, CCNE2 CYP1A2 1111/4885CYP3A4 1137/4885MEN1 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback